司库奇尤单抗治疗4例急性红皮病型银屑病的临床疗效及安全性并文献复习  

Clinical efficacy and safety of secukinumab in the treatment of 4 cases of acute erythrodermic psoriasis and literature review

作　　者：于欣 李邻峰[1] YU Xin;LI Lin-feng(Department of Dermatology,Beijing Friendship Hospital,Capital Medical University,Beijing 100050,China)

机构地区：[1]首都医科大学附属北京友谊医院皮肤科,北京100050

出　　处：《临床和实验医学杂志》2024年第20期2227-2230,共4页Journal of Clinical and Experimental Medicine

基　　金：北京市自然科学基金(编号:7222038)。

摘　　要：目的评价司库奇尤单抗治疗4例急性红皮病型银屑病的临床疗效及安全性,并文献复习。方法回顾性收集2020年1月至2023年12月就诊于首都医科大学附属北京友谊医院接受司库奇尤单抗治疗的红皮病型银屑病的患者进行个案报道并文献综述。共收集4例红皮病型银屑病患者,均采取司库奇尤单抗300 mg/次标准疗法皮下注射,在第0、4、8、12周时记录患者银屑病皮损面积和严重度指数,4例患者均接受至少24周的治疗,观察患者银屑病皮疹面积及严重程度的变化,同时观察药物不良反应,尤其是乙肝及结核的再激活率。结果4例患者潮红情况1周即明显改善,体温恢复正常,治疗4周时,4例达到银屑病严重度指数(PASI)50;治疗12周,4例均达到PASI 75,3例达到PASI 90,所有患者原红皮病型银屑病在治疗后皮疹表现为斑块状银屑病。随访1年,3例维持PASI 90缓解,1例患者PASI 75缓解,皮疹表现为慢性斑块型银屑病。1例80岁患者最长随访2年,均未发生严重药物不良反应。结论司库奇尤单抗治疗急性红皮病型银屑病起效迅速,疗效显著,不良反应较少,为红皮病型银屑病的治疗提供了新的选择。Objective To evaluate the clinical efficacy and safety of secukinumab in the treatment of 4 cases of acute erythrodermic psoriasis and review the literature.Methods The patients with erythrodermic psoriasis who were treated with secukinumab in Beijing Friendship Hospital,Capital Medical University from January 2020 to December 2023 were retrospectively collected for case report and literature review.All four patients received secukinumab 300 mg/subcutaneous injection of the standard therapy at a time.The psoriasis area and severity index of the patients was recorded at weeks 0,4,8,and 12.All 4 patients received treatment for at least 24 weeks.The changes in the area and severity of psoriasis rashes in the patients were observed,and the adverse drug reactions were also observed.Results The flushing situation of the 4 patients improved significantly in 1 week,and the body temperature returned to normal.At 4 weeks of treatment,4 cases achieved psoriasis area and severity index(PASI)50;at 12 weeks of treatment,all 4 cases achieved PASI 75,and 3 cases achieved PASI 90.The rashes of all patients with the original erythrodermic psoriasis showed plaque psoriasis after treatment.After 1-year follow-up,3 cases maintained PASI 90 remission,and 1 patient achieved PASI 75 remission,and the rashes showed chronic plaque psoriasis.One 80-year-old patient was followed up for the longest 2 years,and no serious adverse drug reactions occurred.Conclusion Secukinumab has a rapid onset of action,significant efficacy,and few adverse reactions in the treatment of acute erythrodermic psoriasis,providing a new option for the treatment of erythrodermic psoriasis.

关 键 词：银屑病 生物制剂 红皮病型 司库奇尤单抗 

分 类 号：R758.63[医药卫生—皮肤病学与性病学]